Merck

New Daily Pill Cuts Bad Cholesterol by 60%, Matching Injectable Drugs

Merck's enlicitide, the first oral PCSK9 inhibitor, slashed LDL cholesterol as effectively as injections in a 2,909-person trial. The pill could solve the biggest barrier keeping millions from powerful cholesterol-lowering therapy.